These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 22780876

  • 1. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid.
    Krueger C, Thommes M.
    Pharm Dev Technol; 2013 Feb; 18(1):225-35. PubMed ID: 22780876
    [Abstract] [Full Text] [Related]

  • 2. Properties of pellets manufactured by wet extrusion/spheronization process using kappa-carrageenan: effect of process parameters.
    Thommes M, Kleinebudde P.
    AAPS PharmSciTech; 2007 Nov 09; 8(4):E95. PubMed ID: 18181555
    [Abstract] [Full Text] [Related]

  • 3. Effect of drying on extruded pellets based on kappa-carrageenan.
    Thommes M, Blaschek W, Kleinebudde P.
    Eur J Pharm Sci; 2007 Jun 09; 31(2):112-8. PubMed ID: 17448646
    [Abstract] [Full Text] [Related]

  • 4. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
    Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2006 May 09; 63(1):68-75. PubMed ID: 16325384
    [Abstract] [Full Text] [Related]

  • 5. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
    Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2006 May 09; 63(1):59-67. PubMed ID: 16326085
    [Abstract] [Full Text] [Related]

  • 6. The influence of plate design on the properties of pellets produced by extrusion and spheronization.
    Michie H, Podczeck F, Newton JM.
    Int J Pharm; 2012 Sep 15; 434(1-2):175-82. PubMed ID: 22659150
    [Abstract] [Full Text] [Related]

  • 7. Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.
    Ghanam D, Kleinebudde P.
    Int J Pharm; 2011 May 16; 409(1-2):9-18. PubMed ID: 21335073
    [Abstract] [Full Text] [Related]

  • 8. Influence of MCC II fraction and storage conditions on pellet properties.
    Krueger C, Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2013 Nov 16; 85(3 Pt B):1039-45. PubMed ID: 23872176
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The behavior of different carrageenans in pelletization by extrusion/spheronization.
    Thommes M, Kleinebudde P.
    Pharm Dev Technol; 2008 Nov 16; 13(1):27-35. PubMed ID: 18300097
    [Abstract] [Full Text] [Related]

  • 11. Drug release from MCC- and carrageenan-based pellets: experiment and theory.
    Kranz H, Jürgens K, Pinier M, Siepmann J.
    Eur J Pharm Biopharm; 2009 Oct 16; 73(2):302-9. PubMed ID: 19465119
    [Abstract] [Full Text] [Related]

  • 12. Preliminary assessment of carrageenan as excipient for extrusion/spheronisation.
    Bornhöft M, Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2005 Jan 16; 59(1):127-31. PubMed ID: 15567309
    [Abstract] [Full Text] [Related]

  • 13. Preparing of pellets by extrusion/spheronization using different types of equipment and process conditions.
    Bölcskei É, Regdon G, Sovány T, Ghanam D, Knop K, Kleinebudde P, Pintye-Hódi K.
    Drug Dev Ind Pharm; 2014 Jun 16; 40(6):762-4. PubMed ID: 23596971
    [Abstract] [Full Text] [Related]

  • 14. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion.
    Krause J, Thommes M, Breitkreutz J.
    Eur J Pharm Biopharm; 2009 Jan 16; 71(1):138-44. PubMed ID: 18805483
    [Abstract] [Full Text] [Related]

  • 15. Compression behaviour of kappa-carrageenan pellets.
    Ghanam D, Hassan I, Kleinebudde P.
    Int J Pharm; 2010 May 10; 390(2):117-27. PubMed ID: 20100553
    [Abstract] [Full Text] [Related]

  • 16. Use of extrusion aids for successful production of Kollidon® CL-SF pellets by extrusion-spheronization.
    Loka NC, Saripella KK, Pinto CA, Neau SH.
    Drug Dev Ind Pharm; 2018 Apr 10; 44(4):632-642. PubMed ID: 29183166
    [Abstract] [Full Text] [Related]

  • 17. Production and characterization of pellets using Avicel CL611 as spheronization aid.
    Puah SY, Yap HN, Chaw CS.
    Drug Dev Ind Pharm; 2014 Mar 10; 40(3):418-24. PubMed ID: 23480532
    [Abstract] [Full Text] [Related]

  • 18. Production of spherical pellets by a hot-melt extrusion and spheronization process.
    Young CR, Koleng JJ, McGinity JW.
    Int J Pharm; 2002 Aug 21; 242(1-2):87-92. PubMed ID: 12176229
    [Abstract] [Full Text] [Related]

  • 19. Influence of storage condition on properties of MCC II-based pellets with theophylline-monohydrate.
    Krueger C, Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2014 Oct 21; 88(2):483-91. PubMed ID: 24950003
    [Abstract] [Full Text] [Related]

  • 20. Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties.
    Verheyen P, Steffens KJ, Kleinebudde P.
    Drug Dev Ind Pharm; 2009 Nov 21; 35(11):1325-32. PubMed ID: 19832632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.